Entry Point Capital, LLC Y M Abs Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 17,071 shares of YMAB stock, worth $139,128. This represents 0.13% of its overall portfolio holdings.
Number of Shares
17,071
Previous 6,152
177.49%
Holding current value
$139,128
Previous $74.3 Million
99.7%
% of portfolio
0.13%
Previous 0.11%
Shares
3 transactions
Others Institutions Holding YMAB
# of Institutions
106Shares Held
24.5MCall Options Held
40.3KPut Options Held
400-
Paradigm Biocapital Advisors LP New York, NY4.09MShares$33.3 Million1.93% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$24 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$17.9 Million2.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.04MShares$16.6 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$14.9 Million0.15% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $356M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...